Tumor-infiltrating PD-1+ immune cell density is associated with response to neoadjuvant chemoradiotherapy in rectal cancer

2022 ◽  
Author(s):  
Yusuke Kitagawa ◽  
Takashi Akiyoshi ◽  
Noriko Yamamoto ◽  
Toshiki Mukai ◽  
Yukiharu Hiyoshi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cell Density ◽  
Immune Cell ◽  
Neoadjuvant Chemoradiotherapy

scholarly journals Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response

Oncotarget ◽  
2017 ◽  
Vol 8 (12) ◽  
pp. 19803-19813 ◽  
Author(s):  
Melanie J. McCoy ◽  
Chris Hemmings ◽  
Chidozie C. Anyaegbu ◽  
Stephanie J. Austin ◽  
Tracey F. Lee-Pullen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
T Cell ◽  
Treatment Response ◽  
Cell Density ◽  
Regulatory T Cell ◽  
Neoadjuvant Chemoradiotherapy ◽  
Predict Treatment Response

scholarly journals Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer

2015 ◽  
Vol 113 (12) ◽  
pp. 1677-1686 ◽  
Author(s):  
M J McCoy ◽  
C Hemmings ◽  
T J Miller ◽  
S J Austin ◽  
M K Bulsara ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
T Cell ◽  
Cell Density ◽  
Regulatory T Cell ◽  
Neoadjuvant Chemoradiotherapy ◽  
Complete Response

scholarly journals Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy

2020 ◽  
Vol 9 (9) ◽  
pp. 2775
Author(s):  
Florian Huemer ◽  
Eckhard Klieser ◽  
Daniel Neureiter ◽  
Verena Schlintl ◽  
Gabriel Rinnerthaler ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Immune Cell ◽  
Expression Patterns ◽  
Neoadjuvant Chemoradiotherapy ◽  
Programmed Death ◽  
Impact On Survival ◽  
Positive Score ◽  
Combined Positive Score ◽  
Medical University

Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8—not reached) vs. >1%: not reached, p = 0.03, log-rank). Patients with a PD-L1 TPS ≤1% prior to and after CRT showed an inferior survival compared to all other patients (median: 56.7 months (95% CI: 51.4—not reached) vs. not reached, p = 0.005, log-rank). In multivariate analysis, PD-L1 TPS prior to neoadjuvant CRT (>1% vs. ≤1%, hazard ratio: 0.29 (95% CI: 0.11–0.76), p = 0.01) remained independently associated with survival. In conclusion, low PD-L1 TPS was associated with inferior survival in rectal cancer patients undergoing neoadjuvant CRT. A prospective validation of the prognostic value of PD-L1 expression in rectal cancer patients within a clinical trial is necessitated.

Assessment of the Efficacy of Neoadjuvant Chemoradiotherapy in Rectal Cancer. Experience of an Irish Specialist Colorectal Unit

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
E Nzewi ◽  
E Boyle ◽  
D O'Riordain ◽  
P Neary ◽  
F Keane
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Chemoradiotherapy ◽  
Cancer Experience

scholarly journals Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1539
Author(s):  
Virgílio Souza e Silva ◽  
Emne Ali Abdallah ◽  
Bianca de Cássia Troncarelli Flores ◽  
Alexcia Camila Braun ◽  
Daniela de Jesus Ferreira Costa ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Transforming Growth Factor ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Neoadjuvant Chemoradiotherapy ◽  
Disease Free Survival ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

The heterogeneity of response to neoadjuvant chemoradiotherapy (NCRT) is still a challenge in locally advanced rectal cancer (LARC). The evaluation of thymidylate synthase (TYMS) and RAD23 homolog B (RAD23B) expression in circulating tumor cells (CTCs) provides complementary clinical information. CTCs were prospectively evaluated in 166 blood samples (63 patients) with LARC undergoing NCRT. The primary objective was to verify if the absence of RAD23B/TYMS in CTCs would correlate with pathological complete response (pCR). Secondary objectives were to correlate CTC kinetics before (C1)/after NCRT (C2), in addition to the expression of transforming growth factor-β receptor I (TGF-βRI) with survival rates. CTCs were isolated by ISET and evaluated by immunocytochemistry (protein expression). At C1, RAD23B was detected in 54.1% of patients with no pCR and its absence in 91.7% of patients with pCR (p = 0.014); TYMS− was observed in 90% of patients with pCR and TYMS+ in 51.7% without pCR (p = 0.057). Patients with CTC2 > CTC1 had worse disease-free survival (DFS) (p = 0.00025) and overall survival (OS) (p = 0.0036) compared with those with CTC2 ≤ CTC1. TGF-βRI expression in any time correlated with worse DFS (p = 0.059). To conclude, RAD23B/TYMS and CTC kinetics may facilitate the personalized treatment of LARC.

Sign in / Sign up

Export Citation Format

Share Document